Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) on Wednesday, setting a price target of $202, which is approximately 23.69% above the present share price of $163.31.
Samimy expects Jazz Pharmaceuticals to post earnings per share (EPS) of $2.39 for the second quarter of 2021.
The current consensus among 14 TipRanks analysts is for a Strong Buy rating of shares in Jazz Pharmaceuticals, with an average price target of $204.69.
The analysts price targets range from a high of $235 to a low of $176.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $665.52 million and a net profit of $209.41 million. The company's market cap is $9.2 billion.
According to TipRanks.com, Stifel Nicolaus analyst Annabel Samimy is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.7% and a 50.00% success rate.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.